Efficacy of cabergoline on rapid escalation of dose in men with macroprolactinomas
|
|
- Griffin Hart
- 6 years ago
- Views:
Transcription
1 Indian J Med Res 131, April 2010, pp Efficacy of cabergoline on rapid escalation of dose in men with macroprolactinomas A. Bhansali, R. Walia, P. Dutta, N. Khandelwal *, R. Sialy & S. Bhadada Departments of Endocrinology & * Radiodiagnosis, Postgraduate Institute of Medical Education & Research Chandigarh, India Received December 24, 2008 Background & objectives: Since cabergoline has a long half-life and sustained occupancy of dopamine (D 2 ) receptors in lactotrophs, its doses are slowly built up either monthly or two monthly. This possibly results in delayed normalization of serum prolactin and slow reduction in tumour size. This study was planned to assess the efficacy and safety of rapid escalation of cabergoline doses in men with macroprolactinomas. Materials: Fifteen consecutive men with macroprolactinomas underwent evaluation for anterior pituitary functions, visual fields, quality of life (QOL) score and magnetic resonance imaging (MRI), at baseline and after 6 months of cabergoline therapy. Serum prolactin and testosterone levels were assessed at monthly intervals. Cabergoline was started at a dosage of 0.5 mg twice per week and increased to 1.5 mg twice per week (3 mg ) by the third week, as 3 mg is usually considered as effective dose. Subsequent increase in doses was done as per protocol. Results: The mean age of patients at presentation was 31.7 ± 3.3 yr and duration of symptoms was 25.0 ± 3.6 months. Serum prolactin at baseline was ± μg/l with a tumour volume of 28.9 ± 8.3 cm 3. Eighty six per cent of the patients had visual field defects while 53 per cent had decreased visual acuity. The mean dose of cabergoline required was 3.2 mg/wk. Symptoms improved in majority (93%) of patients after four weeks of cabergoline therapy with a dramatic fall in serum prolactin by 99 per cent from ± to 46.9 ± 14.9 μg/l and it was normalized in 93 per cent of the patients by 8.2 wk. Improvement in visual field defects was noted in all but one, after one month and there was further improvement at 6 months. All patients had >25 per cent reduction in tumour size, and 73 per cent had > 50 per cent reduction after six months of cabergoline therapy. Basal circulating testosterone levels were low in 11 (73%) patients and started improving from first month of cabergoline therapy and became normal in around half of the patients after 6 months. No major side effects were observed requiring discontinuation of cabergoline therapy. Interpretation & conclusions: Our preliminary findings show that rapid build-up of cabergoline doses increases its efficacy as well as rapidity of response in terms clinical improvement, normalization of serum prolactin and gonadal functions and reduction in tumour size, without compromising its safety in men with macroprolactinomas. Further studies with a larger sample size and control group for comparison need to be done to confirm these findings. Key words Cabergoline - dose escalation - macroprolactinomas 530
2 bhansali et al: Rapid dose escalation of cabergoline in macroprolactinomas treatment 531 Prolactinomas are the most common functioning pituitary adenomas. However, these are relatively rare in men; more than 70 per cent of cases occur in women 1. These tumours are typically associated with ovulatory dysfunction and galactorrhoea in women and with hypogonadism in men. Macroprolactinomas usually cause symptoms of mass effect including headaches, visual field defects and hypopituitarism. Dopamine agonists are the first line of treatment in majority of patients with hyperprolactinemic disorders. Bromocriptine, introduced in 1970, is the original formulation against which newer dopamine agonists are compared 2. However, significant proportion of patients (up to 20%) have poor tolerability to the drug at therapeutic doses or have resistance to its effects 3. In addition, because of its short half-life, bromocriptine needs to be administered twice or thrice daily. Cabergoline, a newer dopamine agonist, has an advantage of once or twice weekly administration with minimal side-effects 4. Like bromocriptine, cabergoline is initiated at low doses and built-up slowly, though it is much better tolerated. It is apparent that doses and rapidity of dose escalation of dopamine agonists in treatment of hyperprolactinemia needs to be individualized 3. In patients with symptomatic chiasmal compression, urgent shrinkage of the tumour is important, whereas in patient with a microadenoma, a less rapid escalation of dopamine agonists may be required. The recommended schedule for escalation of cabergoline doses varies from monthly to two monthly increase with attaining the maximum effective dose of mg/wk 5,6. This relatively takes a longer time to normalize serum prolactin and reduction in tumour size is quite variable 4-6. However, clinical significance of rapid versus slow dose escalation of cabergoline has not been examined earlier. Therefore, this study was planned to assess efficacy and safety of rapid escalation of cabergoline doses in men with macroprolactinomas. Material & Methods Study design: Fifteen consecutive men with macroprolactinomas attending the Endocrine Clinic of the Nehru Hospital at Postgraduate Institute of Medical Education and Research, Chandigarh, India, during September 2004 to June 2006 were recruited for the study. A written informed consent was obtained from all these subjects. The study was approved by the Institute s Ethics Committee. Selection criteria: Post-pubertal men with macroprolactinomas (any tumour diameter > 10 mm) and serum prolactin level > 150 μg/l were recruited. None had any other systemic illness and they were not on any drug known to cause hyperprolactinemia. The patients were assessed at monthly intervals and at each visit, history and physical examination was carried out and investigated as per the following protocol during the six month study period. At the time of recruitment, at 0800 h, blood samples (10 ml) were drawn for the following investigations: haemogram, renal and liver function tests, and pooled samples ( two aliquots of similar volume at 20 min intervals) for serum prolactin, T3, T4, TSH, cortisol, LH, FSH and testosterone. Testosterone and prolactin levels were repeated at monthly intervals. Magnetic resonanes imaging (MRI) of the pituitary region was done at baseline and after six months of therapy. Tumour size was calculated by Dichiro s formula 7 ( п/6 x antero-posterior diameter x vertical diameter x transverse diameter). Decrease in tumor size of >25 per cent was considered as significant. Visual field defects were assessed on a 76 point scale with the Humphrey automated computerized perimeter, at 0, 1 and 6 months or in-between if any deterioration of vision was noticed. Quality of life (QOL) score was assessed at 0 and 6 months by questionnaire method 8. Serum prolactin (N,5-20 μg/l), T3(N, ng/ml), T4(N, μg/dl) and TSH(N mIU/l) levels were assessed by immunoradiometric/radioimmuno assay using commercial kits (Advia Centaur, Inc, Germany) with intra- and inter- assay coefficients of variation of < 8 per cent. Serum testosterone (N, 9-27 nmol/l) and cortisol (0800 h, nmol/l) were estimated with in-house radioimmunoassay 9. Serum LH, FSH were done with enzyme linked immunosorbent assay (ELISA) using commercial kits (Syntron Bio research, Inc., USA) with sensitivity of assay being 1.25 IU/l for both. The following criteria were used to define pituitary hormone deficiency. Serum T 4 level of <4 μg/dl with low or normal TSH was considered as secondary hypothyroidism, serum cortisol at 0800 h >350 nmol/l as adrenal sufficiency, <100 nmol/l as adrenal insufficiency and those with cortisol level between > nmol/l were considered to be in the grey zone and were supplemented only during stress 10,11. Serum testosterone level of <9 nmol/l was defined as hypogonadism. Treatment protocol: Tablet Cabergoline (Caberlin, Sun Pharmaceutical, Goa, India) was prescribed at night with food; first week : 0.5 mg twice per week, second week: 1.0 mg twice per week and third week: 1.5 mg
3 532 INDIAN J MED RES, April 2010 twice per week (e.g., Monday and Thursday), followed by continuation of the same dose till eighth week, as the usual effective dose (~3mg/wk) was already achieved by the third week. At the end of the eighth week, the dose was planned to be increased by 1.0 mg/wk, if the serum prolactin levels had not been normalized (<20 μg/l) by that time. Second hike in doses was planned at the end of sixteenth week if the serum prolactin levels remained above the normal range. Statistical analysis: ANOVA was used for repeated measures to evaluate the effect of cabergoline throughout the follow up. Various hormonal parameters pre- and post-therapy were analyzed using Wilcoxon s test. Statistical significance was set at 5 per cent. Correlations were performed by calculating the Spearman s coefficient, as the data were not normally distributed. Results The mean age of these patients at presentation was 31.7 ± 3.3 yr with a range of yr, and duration of symptoms 25.0 ± 3.6 months with a range of 1-36 months. All the patients registered completed the study without any drop-out. The presenting symptoms and signs are summarized in Table I. Serum prolactin at baseline was ± μg/l, with a range of μg/l. All patients had macroprolactinomas with a tumour volume of 29.0 ± 8.3 cm 3, varying from 1.3 to 92.2 cm 3. There was a correlation between tumour size and serum prolactin levels (r=0.60, P=0.05). The mean and maximum dose of cabergoline required was 3.2 and 4 mg per week respectively. All patients were euthyroid including one, who was on replacement with L-thyroxine therapy. One patient had 0800 h serum cortisol 50 nmol/l and received hydrocortisone replacement and 7 patients had 0800 h serum cortisol between > nmol/l and only one of them was symptomatic and thereby required cortisol replacement. The hormonal parameters at baseline are presented in Table II. Headache disappeared in 12 (80%) patients after one month and in all patients after 2 months of cabergoline therapy. It reappeared in one patient at four months of therapy because of pituitary apoplexy. Visual field defects and decreased visual acuity were present in 86 and 55 per cent of patients respectively and these markedly improved after one month of therapy and they further improved at 6 months. Libido improved in 12 (80%) patients after one month of therapy and in 93 per cent by 2 months of therapy. Table 1. Symptoms and signs at the time of presentation in patients with macroprolactinomas Symptoms No of patients ( % ) Headache 15 ( 100 ) Loss of libido 15 ( 100 ) Visual symptoms 13 ( 86 ) Erectile dysfunctions 10 ( 67 ) Gynaecomastia 7 ( 47 ) Galactorrhoea 3 ( 20 ) Decreased shaving frequency 3 ( 20 ) Infertility 3 ( 20 ) Arrested puberty 1 ( 7 ) Table II. Hormonal parameters and tumour volume at baseline and after 6 months of cabergoline therapy in patients with macroprolactinomas (n=15) Parameters Pre-therapy mean ±SEM baseline ± Post-therapy mean ±SEM 6 months 6.0 ±2.6 ** ( ) Prolactin (μg/l) (range) ( ) Testosterone (nmol/l) 7. 4 ± ±1.13 * LH(IU/l) 2.0 ± ± 0.46 FSH(IU/l) 1.4 ± ± 0.2 Tumour volume (cm 3 ) 29.0 ± ± 2.3 ** P * <0.005 ** < compared to pre-therapy Erectile dysfunctions improved in 8 of 10 patients after one month of therapy and in 9 of 10 after 2 months of therapy. One patient continued to have impaired libido and erectile dysfunctions, despite normalization of prolactin, but continued to have very low basal testosterone after 6 months of therapy. Galactorrhoea disappeared in 2 of the 3 patients after 3 months of therapy and in the remaining after 4 months of cabergoline therapy. All patients had a precipitous fall in serum prolactin after one month of cabergoline therapy to 46.9 ±14.9 μg/l, with a range of μg/l. The drop was statistically significant (P<0.001) with a mean percentage decrease of 99 per cent from baseline. In 6 patients, serum prolactin became normal ( 20 μg/l) at 1 month, in 9 by 2 months and in remaining six patients, it continued to decrease and became normal in all but one, in whom serum prolactin was 42.2 μg/l with >95 per cent decrease at 6 months. However, mean serum prolactin was normalized in 93 per cent of the patients by 8.2 wk. At six months, the serum prolactin was 6.0 ± 2.6 μg/l with a range from 1.00 to 42.2 μg/l. (Table II). There was a significant correlation between pretreatment tumour size and maximum required doses of cabergoline (R=0.52 P=0.04). Eleven patients had subnormal serum testosterone
4 bhansali et al: Rapid dose escalation of cabergoline in macroprolactinomas treatment 533 Fig. MR T1W image (a), coronal sections showing hyper-intense sellar mass with supra-sellar extension with a tumour volume of 9.3 cm3, follow up MR T1W image; (b) showing appreciable reduction (tumour volume 2.8 cm3, 71%) in sellar mass after six months of cabergoline therapy. (<9nmol/l) at baseline and it started improving from the first month in all patients and became normal at six months in 5 of the 11 patients after therapy. Serum testosterone levels took a longer time to attain normalcy as compared to the serum prolactin levels, except in one, in whom serum testosterone became normal despite raised levels of serum prolactin. However, there was no correlation found between increase in serum testosterone and decrease in serum prolactin levels at any point of time. Before therapy, all the patients had low normal basal levels of LH and FSH. After cabergoline therapy at six months, LH and FSH levels increased in all patients, though it could not reach statistical significance. Repeat MRI for pituitary after 6 months of therapy revealed a significant reduction in tumour size from 29.0 ± 8.3 to 5.8 ± 2.3 cm3 (P<0.001), accounting for a mean reduction of 66.8 per cent. All patients had > 25 per cent reduction in tumour size and 73 per cent had 50 per cent reduction after cabergoline therapy (Fig.). There was no new onset of hormone deficiency and serum cortisol at 0800 h became normal (>350 nmol/l) in seven of eight patients. No major side effects of cabergoline were observed requiring discontinuation of the therapy. One patient each complained of nausea and sleepiness, which subsided after 2 wk of therapy. One patient developed apoplexy after four months of therapy. He was managed conservatively with steroids and subsequently improved. Discussion The dose escalation of cabergoline in patients with macroprolactinomas in previous studies had varied from monthly to two monthly. A study by Biller et al5 showed normalization of serum prolactin in 73 per cent of the patients by mean duration of 19 wk with a mean dose of 1.82 mg with a monthly escalation. Similarly in other studies normalization of serum prolactin was delayed by wk with a monthly or three monthly escalation of cabergoline and the number of patients achieving normalization of serum prolactin did not increase further (50 to 83.3%) despite continued escalation in doses even by the end of the study period4-6,12-13 (Table III). In the present study, serum prolactin became normal in 93 per cent of the patients with a mean duration of 8.2 wk. The mean decrease in serum prolactin was 99 per cent by four weeks, however a similar decrease (93 to 99%) in prolactin was achieved in other studies with a time lag of 48 to 160 wk4-6,11,12. This supports the notion that rapid hike in doses of cabergoline decreases serum prolactin levels faster and it becomes normal in the majority of patients earlier. We observed a significant correlation between pre-treatment tumour size and the maximum required doses of cabergoline substantiating the fact that the larger tumours require higher doses to respond as compared to smaller macroprolactinomas. This observation has not been documented in previous studies. However, this may possibly be explained as larger tumours are likely to harbour more number of D2 receptors.
5 534 INDIAN J MED RES, April 2010 Authors Biller et al Colao et al * Ferrari et al Corsello et al Shimon et al No of patients Table III. Studies showing the efficacy of cabergoline in prolactinomas Cabergoline schedule mg once/wk ed by 0.25 mg after 4 wk followed by of 0.5 mg/ wk every 4 wk till PRL normalization mg once/wk, 0.5 mg twice/wk. Dose adjustment at 2 months depending upon PRL levels to 0.5 mg/wk and increased up till 10.5 mg/ wk mg thrice/wk. Dose adjustment at 3 months depending upon PRL levels mg twice/wk-1 st wk. 0.5 mg thrice/wk-2 nd wk. Dose adjustment at 2-3 months depending upon PRL levels Present study * mg twice/ wk,1.0 mg twice/wk-2nd wk,1.5 mg twice/wk-3rd wk. * Drug naïve patients PRL, prolactin Study Duration (months) Mean/ Median dose (mg) (median) (median) Mean duration to normalize PRL (wk) % decrease in prolactin (time in wk) % of patients in whom prolactin got normalized % of patients in whom tumour size decreased 25 % (mean % reduction) (48) (31) (104) ( 74 )??(?) (?) (160) (65) (101.2) (47) (66) There was a remarkable improvement in clinical symptomatology including headache, libido and potency after 4 wk of therapy. This is in contrast to the previous studies, where such improvement has been reported after 8-24 wk of therapy 6, Improvement in vision has been reported in per cent of patients in various series after a period of 4-24 wk In this study, all patients who had decrease in vision at baseline experienced improvement within 4 wk of therapy. The improvement in QOL score correlated with decrease in serum prolactin levels rather than increase in serum testosterone levels. This was observed in more than half (55%) of the patients, where decrease in serum prolactin levels were associated with improved libido and potency despite subnormal testosterone levels as shown by others also 6,17. Previous studies have shown mean tumour reduction of per cent over a duration of 3 months to 8 yr and the response rate increased with increasing duration of therapy 4-6, Mean tumour volume reduction by 66.8 per cent and tumour shrinkage of > 25 per cent in all the patients within 6 months in the present study supports the hypothesis of rapid build up of cabergoline therapy. The most commonly reported side effects with dopamine agonists are dizziness, headache, nausea and weakness 18,19. As it was likely that rapid escalation of cabergoline doses would have led to more frequent side effects. However, in the present study, there was no increased incidence of adverse drug reactions and none of the patients required discontinuation of therapy. One patient had an episode of apoplexy after four months of therapy, which is unlikely to be the result of rapid escalation of cabergoline doses, as a stable maintenance dose was achieved much earlier during the first month of therapy. The efficacy of cabergoline is dose related and determined by percentage of D 2 receptor occupancy and prolonged receptor affinity 20. The patients, who respond to increasing dosages of cabergoline, probably do so by
6 bhansali et al: Rapid dose escalation of cabergoline in macroprolactinomas treatment 535 an increased receptor occupancy with higher doses. It has been observed earlier that the patients, who do not respond initially, may remain resistant even after further increasing the doses 3. This is explained by the fact that in macroadenomas, there are sub-populations of tumour cells with D 2 receptors if remained unoccupied initially, may have a growth advantage and such tumours may not respond to increasing doses of cabergoline later on. This was evident in the present study by the fact that maximal number of patients achieved normalization of serum prolactin by eight weeks and this number did not increase further with escalation of cabergoline doses. However, the limitations of the present study are the smaller number of patients and lack of a control group who would have been treated with conventional treatment protocol, to compare the efficacy with the suggested protocol in the present study. In conclusion, rapid build-up of cabergoline doses increases its efficacy as well as rapidity of response without compromising its safety. The results are preliminary but promising and to substantiate these findings further larger and controlled studies are needed. Conflict of interest: There was no conflict of interest to declare. References 1. Mindermann T, Wilson CB. Age-related and gender related occurrence of pituitary adenomas. Clin Endocrinol 1994; 41 : Molitch ME, Elton RL, Blackwell RE, Cardwells B, Chang RJ, Jaffe R, et al. Bromocriptine as primary therapy for prolactin secreting macroadenomas : results of a prospective multicentre study. J Clin Endocrinol Metab 1985; 60 : Molitch ME. Medical management of prolactin secreting pituitary adenomas. Pituitary 2002; 5 : Corsello SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA, et al. Giant prolactinomas in men: efficacy of caberoline treatment. Clin Endocrinol 2003; 58: Biller BMK, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, et al. Treatment of prolactin secreting macroadenoma with once weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996; 81 : Colao A, Vitale G, Cappabianca P, Briganti F, Ciccarelli A, De Rosa M, et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24 months treatment on prolactin levels, tumor mass, recovery of pituitary function and semen analysis. J Clin Endocrinol Metab 2004; 89 : Abbond CF. Louts ER. Diagnosis of pituitary tumors. Endocrinol Metab Clin N Am 1988: 17 : Heinemann LA, Moor C, Dinger JC, Stoehr D. Sensitivity and outcome measures of androgens; the AMS scale Health quality life outcomes. Health Qual Life Outcomes 2006; 4 : Dash RJ, England BG, Midgley AR Jr., Niswender GD. A specific, non-chromatographic radioiammunoassay for human plasma cortisol. Steroids 1975; 26 : Inder WJ, Hunt PJ. Glucocorticoid replacement in pituitary surgery: Guidelines for perioperative assessment and management. J Clin Endocrinol Metab 2002; 87 : Hagg E, Asplund K, Lithner F. Value of basal plasma cortisol assays in the assessment of the pituitary adrenal axis. Clin Endocrinol 1987; 44 : Ferrari CI, Abstract R, Bevan JS, Brabant G, Ciccarelli E, Mottta T, et al. Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol 1997; 46 : Shimon I, Benbassat C, Hadani M. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur J Endocrinol 2007; 156 : De Rose M, Zarrilli S, Vitale G, Di somma C, Orio F, Tauchmanova L, et al. Six months treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. J Clin Endocrinol Metab 2004; 89 : De Rosa M, Colao A, Di Sarno A, Ferone D, Landi ML, Zarrilli S, et al. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur J Endocrinol 1998; 138 : Verhert J, Abs R, Maiter D, Vandeweghe M, Velkeniers B, Mockel J, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999; 84 : De Rose M, Ciccarelli A, Zarrilli S, Guerra E, Gaccione M, Disarno A, et al. The treatment with cabergoline for 24 months normalizes the quality of seminal fluid in hyperprolactinaemic males. Clin Endocrinol 2006; 64 : Page SR, Nussey SS. Cabergoline therapy of a large prolactinoma in a bromocriptine intolerant patient. J Obstet Gynaecol 1989; 10 : Ciccarelli E, Camanni F. Diagnosis and drug therapy of prolactinoma. Drugs 1996; 51 : Ferrari C, Barbieri C, Caldava R, Music M, Codecasa F, Paracchi A, et al. Long lasting prolactin lowering effect of cabergoline a new dopamine agonist in hyperprolactinemic patients. J Clin Endocrinol Metab 1986; 63 : Reprint requests: Dr Anil Bhansali, Professor & Head, Department of Endocrinology, Postgraduate Institute of Medical Education & Research, Chandigarh , India anilbhansali_endocrine@rediffmail.com
Prolactin-Secreting Pituitary Adenomas (Prolactinomas) The Diagnostic Pathway (11-2K-234)
Prolactin-Secreting Pituitary Adenomas (Prolactinomas) The Diagnostic Pathway (11-2K-234) Common presenting symptoms/clinical assessment: Pituitary adenomas are benign neoplasms of the pituitary gland.
More informationEfficacy and Safety of Cabergoline as First Line Treatment for Invasive Giant Prolactinoma
J Korean Med Sci 2009; 24: 874-8 ISSN 1011-8934 DOI: 10.3346/jkms.2009.24.5.874 Copyright The Korean Academy of Medical Sciences Efficacy and Safety of Cabergoline as First Line for Invasive Giant Prolactinoma
More informationMetoclopramide Domperidone. HYPER- PROLACTINAEMIA: the true and the false problems
Modern management of Hyperprolactinaemia Didier DEWAILLY, M.D. Department of Endocrine Gynaecology and Reproductive Medicine, Hôpital Jeanne de Flandre, C.H.R.U., 59037 Lille, France 1 Metoclopramide Domperidone
More informationGLMS CME- Cell Group 5 10 April Greenlane Medical Specialists Pui-Ling Chan Endocrinologist
GLMS CME- Cell Group 5 10 April 2018 Greenlane Medical Specialists Pui-Ling Chan Endocrinologist Pituitary case one Mrs Z; 64F Seen ORL for tinnitus wax impaction MRI Head Pituitary microadenoma (3mm)
More informationManifestations of Hyperprolactinoma and its Management by Bromocriptine and Cabergoline
JKAU: Med. Sci., Vol. 15 No. 1, pp: 51-62 (2008 A.D / 1429 A.H.) Manifestations of Hyperprolactinoma and its Management by Bromocriptine and Cabergoline Faiza A. Qari, FRCP, ABIN Department of Medicine,
More informationACLEAR-CUT GENDER difference exists in the clinical
0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(2):621 625 Printed in U.S.A. Copyright 2004 by The Endocrine Society doi: 10.1210/jc.2003-030852 Six Months of Treatment with
More informationReproductive Health and Pituitary Disease
Reproductive Health and Pituitary Disease Janet F. McLaren, MD Assistant Professor Division of Reproductive Endocrinology and Infertility Department of Obstetrics and Gynecology jmclaren@uabmc.edu Objectives
More informationA Combined Case of Macroprolactinoma, Growth Hormone Excess and Graves' Disease
A Combined Case of Macroprolactinoma, Growth Hormone Excess and Graves' Disease Z Hussein, MRCP*, B Tress**, P G Cohnan, FRACP***... 'Department of Medicine, Hospital Putrajaya, Putrajaya, Presint 7, 62250
More informationCase Report Rapid Pituitary Apoplexy Regression: What Is the Time Course of Clot Resolution?
Case Reports in Radiology Volume 2015, Article ID 268974, 5 pages http://dx.doi.org/10.1155/2015/268974 Case Report Rapid Pituitary Apoplexy Regression: What Is the Time Course of Clot Resolution? Devon
More informationCabergoline in the Treatment of Hyperprolactinemia: A Study in 455 Patients
Cabergoline in the Treatment of Hyperprolactinemia: A Study in 455 Patients Johan Verhelst, Roger Abs, Dominique Maiter, Annick van den Bruel, Mark Vandeweghe, Brigitte Velkeniers, Jean Mockel, Gerard
More informationGender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia
European Journal of Endocrinology (2003) 148 325 331 ISSN 0804-4643 CLINICAL STUDY Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia Annamaria Colao,
More informationMechanism of hyperprolactinemia
Hyperprolactinemia Mechanism of hyperprolactinemia Causes of hyperprolactinemia Hormone-producing pituitary tumors Prolactinoma Acromegaly Hypothalamic/pituitary stalk lesion Tumors, cysts (craniopharyngeoma,
More informationClinical Follow-up of Long-term Treatments for Hyperprolactinaemia in Women
Hyperprolactinaemia a report by Anna-Lena Hulting and Katarina Berinder Clinical Follow-up of Long-term Treatments for Hyperprolactinaemia in Women Professor of Endocrinology and Diabetology, Karolinska
More informationSharon maslovitz Lis Maternity Hospital
Sharon maslovitz Lis Maternity Hospital Case report Chief complaint 27 yo, with PMC @ 31+3w, BCBA twins Complaints of severe rt parietal and retrobulbar headaches Medical background Healthy until 24yo
More informationPituitary Tumors and Incidentalomas. Bijan Ahrari, MD, FACE, ECNU Palm Medical Group
Pituitary Tumors and Incidentalomas Bijan Ahrari, MD, FACE, ECNU Palm Medical Group Background Pituitary incidentaloma: a previously unsuspected pituitary lesion that is discovered on an imaging study
More informationPITUITARY: JUST THE BASICS PART 2 THE PATIENT
PITUITARY: JUST THE BASICS PART 2 THE PATIENT DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none Steps taken to review and
More informationPituitary Disease Resident Tutorial 2017
Pituitary Disease Resident Tutorial 2017 Sarat Sunthornyothin MD Division of Endocrinology and Metabolism King Chulalongkorn Memorial Hospital Pituitary Anatomy hypophyseal portal system direct arterial
More informationProcess / Evidence Class. Clinical Assessment / III
Table 2: Endocrine Author Cozzi et al (2009) 1 Study Design: Prospectively followed case series. Fourteen patients had pre-op hypocortisolism. Patient Population: Seventy-two adult patients who underwent
More informationCase Report Successful Pregnancy in a Female with a Large Prolactinoma after Pituitary Tumor Apoplexy
Case Reports in Obstetrics and Gynecology Volume 2013, Article ID 817603, 4 pages http://dx.doi.org/10.1155/2013/817603 Case Report Successful Pregnancy in a Female with a Large Prolactinoma after Pituitary
More informationEvaluation and Management of Pituitary Failure. Dr S. Ali Imran MBBS, FRCP (Edin), FRCPC Professor of Medicine Dalhousie University, Halifax, NS
Evaluation and Management of Pituitary Failure Dr S. Ali Imran MBBS, FRCP (Edin), FRCPC Professor of Medicine Dalhousie University, Halifax, NS Conflict of Interest None Objectives Diagnostic approach
More informationHyperprolactinemia: N hidshi i MD. Nahid Shirazian MD. Internist, Endocrinologist
Diagnosis and Treatment of Hyperprolactinemia: p N hidshi i MD Nahid Shirazian MD. Internist, Endocrinologist An Endocrine Society Clinical Practice Guideline (J Clin Endocrinol Metab 96: 273 288, 2011)
More informationJACK L. SNITZER, DO INTERNAL MEDICINE BOARD REVIEW COURSE 2018 PITUITARY
JACK L. SNITZER, DO INTERNAL MEDICINE BOARD REVIEW COURSE 2018 PITUITARY JACK L. SNITZER, D.O. Peninsula Regional Endocrinology 1415 S. Division Street Salisbury, MD 21804 Phone:410-572-8848 Fax:410-572-6890
More informationThe effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas
Clinical Endocrinology (2000) 53, 53±60 The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas Antonella Di Sarno, Maria Luisa Landi,
More informationGalactorrhea in Subclinical Hypothyroidism. Division of Endocrinology and Metabolism,
Endocrinol. Japon. 1987, 34 (4), 539-544 Galactorrhea in Subclinical Hypothyroidism TAKAJI TAKAI, KUNIHIRO YAMAMOTO, KOSHI SAITO, KAZUKO ANDO, TOSHIKAZU SAITO AND TAKESHI KUZUYA Division of Endocrinology
More informationHYPOTHALAMO PITUITARY GONADAL AXIS
HYPOTHALAMO PITUITARY GONADAL AXIS Physiology of the HPG axis Endogenous opioids and the HPG axis (exerciseinduced menstrual disturbances) Effects of the immune system on the HPG axis (cytokines: interleukins
More informationSexual dysfunction of chronic kidney disease. Razieh salehian.md psychiatrist
Sexual dysfunction of chronic kidney disease Razieh salehian.md psychiatrist Disturbances in sexual function are a common feature of chronic renal failure. Sexual dysfunction is inversely associated with
More informationTreating Cystic Prolactinomas with Dopamine Agonists: Partial Cabergoline Resistance and Considering Dose Reduction
Treating Cystic Prolactinomas with Dopamine Agonists: Partial Cabergoline Resistance and Considering Dose Reduction Mohammad Talha Rauf, MD Internal Medicine Resident PGY3 Dania AbuShanab, MD Julie Samantray,
More informationGiant Prolactinomas: Report of 6 Cases and Review of Literature
American Journal of Medicine Studies, 2016, Vol. 4, No. 1, 11-16 Available online at http://pubs.sciepub.com/ajms/4/1/2 Science and Education Publishing DOI:10.12691/ajms-4-1-2 Giant Prolactinomas: Report
More informationPituitary Adenomas: Evaluation and Management. Fawn M. Wolf, MD 10/27/17
Pituitary Adenomas: Evaluation and Management Fawn M. Wolf, MD 10/27/17 Over 18,000 pituitaries examined at autopsy: -10.6% contained adenomas (1.5-27%) -Frequency similar for men and women and across
More informationCSF RHINORRHEA: AN EARLY COMPLICATION OF DOPAMINE-SENSITIVE MACROPROLACTINOMA
Case Report CSF RHINORRHEA: AN EARLY COMPLICATION OF DOPAMINE-SENSITIVE MACROPROLACTINOMA Amitha Padmanabhuni, MD 1 ; Rachel Hopkins, MD 1 ; Lawrence Chin, MD 2 ; Ruban Dhaliwal, MD, MPH 1 ABSTRACT Objective:
More informationOperative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients
European Journal of Endocrinology (2008) 158 11 18 ISSN 0804-4643 CLINICAL STUDY Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients J Kreutzer,
More informationNeuroendocrine Disorders in Women
Neuroendocrine Disorders in Women Ursula B. Kaiser, M.D. Chief, Division of Endocrinology, Diabetes and Hypertension Brigham and Women s Hospital Professor of Medicine, Harvard Medical School Case Presentation
More informationCYSTIC PROLACTINOMA: A SURGICAL DISEASE?
AACE Clinical Case Reports Rapid Electronic Articles in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited,
More informationProfessor Ian Holdaway. Endocrinologist Auckland District Health Board
Professor Ian Holdaway Endocrinologist Auckland District Health Board A land of milk and giants hormonesecreting pituitary tumours I M Holdaway, Endocrinologist, Auckland Acromegaly Prolactinomas Cushing
More informationIntroduction to Endocrinology. Hypothalamic and Pituitary diseases Prolactinoma + Acromegaly
Introduction to Endocrinology. Hypothalamic and Pituitary diseases Prolactinoma + Acromegaly Dr. Peter Igaz MD PhD DSc 2nd Department of Medicine Semmelweis University Fields of Endocrinology Diseases
More informationProlactin is a pituitary-derived hormone that plays a
Diagnosis and management of hyperprolactinemia Review Synthèse Omar Serri, Constance L. Chik, Ehud Ur, Shereen Ezzat Abstract PROLACTIN IS A PITUITARY HORMONE that plays a pivotal role in a variety of
More informationPituitary tumour apoplexy within prolactinomas in children: a more aggressive condition?
https://doi.org/10.1007/s11102-018-0900-8 Pituitary tumour apoplexy within prolactinomas in children: a more aggressive condition? Elizabeth Culpin 1 Matthew Crank 1 Mark Igra 2 Daniel J. A. Connolly 2
More informationCase report. Open Access. Abstract
Open Access Case report Hyperthyroidism unmasked several years after the medical and radiosurgical treatment of an invasive macroprolactinoma inducing hypopituitarism: a case report Luca Foppiani 1 *,
More informationPituitary for the General Practitioner. Marilyn Lee Consultant physician and endocrinologist
Pituitary for the General Practitioner Marilyn Lee Consultant physician and endocrinologist Pituitary tumours Anterior/posterior pituitary Extension of adenoma upwards/downwards/sideways Producing too
More informationMRI BRAIN FINDINGS IN PATIENTS WITH HIGH SERUM PROLACTIN LEVELS
ORIGINAL ARTICLE MRI BRAIN FINDINGS IN PATIENTS WITH HIGH SERUM PROLACTIN LEVELS Seema Gul 1, Muhammad Naeem 2, Muhammad Zia ul Islam Khan 3, Muhammad Adil 4, Syed Hussain Abbas 5, Ayasha Khan 6, Syeda
More informationpanhypopituitarism Pattawan Wongwijitsook Maharat Nakhon Ratchasima hospital 17 Nov 2013
panhypopituitarism Pattawan Wongwijitsook Maharat Nakhon Ratchasima hospital 17 Nov 2013 PITUITARY GLAND (HYPOPHYSIS CEREBRI) The master of endocrine glands master of endocrine glands It is a small oval
More informationPituitary Disorders Suranut Charoensri, MD
Pituitary Disorders Suranut Charoensri, MD Division of Endocrinology and Metabolism Department of Medicine Faculty of Medicine, Khon Kaen University Anatomical Landmarks Nat Rev Endocrinol 2014;10:423-435
More informationPituitary Interactive Case Presentations Focus on: Hyperprolactinemia
HYPERPROLACTINEMIA Pituitary Interactive Case Presentations Focus on: Hyperprolactinemia March 6, 2016 Beverly MK Biller, MD Massachusetts General Hospital/Harvard Medical School Hyperprolactinemia is
More informationPituitary apoplexy 台北榮總內分泌新陳代謝科主治醫師林怡君
Pituitary apoplexy 台北榮總內分泌新陳代謝科主治醫師林怡君 Williams text book of endocrinology 11 th e Anterior pituitary hormone 10-20% of pituitary cells, increase to 40% during AP PRL releasing factors: TRH, oxytocin,
More informationEvaluation of endocrine tests. A: the TRH test in patients with hyperprolactinaemia
ORIGINAL ARTICLE Evaluation of endocrine tests. A: the TRH test in patients with hyperprolactinaemia R. Le Moli, E. Endert, E. Fliers *, M.F. Prummel, W.M. Wiersinga Department of Endocrinology and Metabolism,
More informationBrain and optic chiasmal herniation following cabergoline treatment for a giant prolactinoma: wait or intervene?
HORMONES 2014, 13(2):290-295 Case report Brain and optic chiasmal herniation following cabergoline treatment for a giant prolactinoma: wait or intervene? Labrini Papanastasiou, 1 Stelios Fountoulakis,
More informationPituitary Gland Disorders
Pituitary Gland Disorders 1 2 (GH-RH) (CRH) (TRH) (TRH) (GTRH) (GTRH) 3 Classification of pituitary disorders: 1. Hypersecretory diseases: a. Acromegaly and gigantism: Usually caused by (GH)-secreting
More informationFemale Reproductive Endocrinology
Female Reproductive Endocrinology Dr. Channa Jayasena PhD MRCP FRCPath Clinical Senior Lecturer & Consultant Endocrinologist Department of Gynaecology, Hammersmith Hospital Anovulation is a common cause
More informationStatus epilepticus induced by treatment with dopamine agonist therapy for giant prolactinoma: a case report
Koguchi et al. Journal of Medical Case Reports (2019) 13:18 https://doi.org/10.1186/s13256-018-1939-x CASE REPORT Status epilepticus induced by treatment with dopamine agonist therapy for giant prolactinoma:
More informationHyperprolactinemia in A 15-Year-Old Girl with Primary Amenorrhea
Clin Pediatr Endocrinol 1996; 5(2), 61-66 Copyright (C) 1996 by The Japanese Society for Pediatric Endocrinology Hyperprolactinemia in A 15-Year-Old Girl with Primary Amenorrhea Toshihisa Okada, Soroku
More informationSharon maslovitz Lis Maternity Hospital
Sharon maslovitz Lis Maternity Hospital Case report Chief complaint 27 yo, with PMC @ 31+3w, BCBA twins Complaints of severe rt parietal and retrobulbar headaches Conditions that may cause episodic headaches:
More informationFunctional Pituitary Adenomas. Fawn M. Wolf, MD 2/2/2018
Functional Pituitary Adenomas Fawn M. Wolf, MD 2/2/2018 Outline Prolactinoma Acromegaly Cushing s disease Thyrotroph adenomas Gonadotroph adenomas Hyperprolactinemia Clinically apparent prolactinomas:
More informationHyperprolactinaemia: when MRI is indicated?
Original Article Hyperprolactinaemia: when MRI is indicated? Wasan I. Majeed 1 F.I.B.M.S Mohammed Abd Kadhim 2 F.I.B.M.S Abstract: Design: This prospective study was carried out at the magnetic resonance
More informationKingdom of Bahrain Arabian Gulf University College of Medicine and Medical Sciences. Endocrinology. (Review) Year 5 Internal Medicine
Kingdom of Bahrain Arabian Gulf University College of Medicine and Medical Sciences Endocrinology (Review) Year 5 Internal Medicine Presented by: Dr. Mona Arekat Prepared by: Ali Jassim Alhashli Case (1):
More informationABNORMAL PITUITARY FUNCTION
Overview ABNORMAL PITUITARY FUNCTION Specialist Portfolio Seminar Katie Jones Sandwell and West Birmingham Hospitals NHS Trust Anterior pituitary overview Posterior pituitary overview Pituitary dysfunction
More information2.0 Synopsis. Lupron Depot M Clinical Study Report R&D/09/093. (For National Authority Use Only) to Part of Dossier: Name of Study Drug:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: Name of Study Drug: Volume: Abbott-43818 (ABT-818) leuprolide acetate for depot suspension (Lupron Depot ) Name of
More informationPrakash Abraham, MB, BS, MD, MRCP, and John S. Bevan, MD, FRCP (Edin) INTRODUCTION
2/Prolactinoma 21 2 Prolactinoma Prakash Abraham, MB, BS, MD, MRCP, and John S. Bevan, MD, FRCP (Edin) CONTENTS INTRODUCTION CLINICAL FEATURES OF PROLACTINOMA DIAGNOSTIC INVESTIGATIONS TREATMENT OF PROLACTINOMA
More informationThe subjects were participants in a Dutch national prospective study, running from April
Supplemental Data Subjects The subjects were participants in a Dutch national prospective study, running from April 1, 1994 to April 1, 1996. Infants with neonatal screening results indicative of CH-C
More informationORIGINAL ARTICLE. The incidence of hyperprolactinaemia and associated hypothyroidism: local experience from Lahore
PJNM 2011, 1:4955 331691 2011 Pakistan Society of Nuclear Medicine ORIGINAL ARTICLE The incidence of hyperprolactinaemia and associated hypothyroidism: local experience from Lahore Affia Tasneem 1, Ismat
More informationWithdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia
original article Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia Annamaria Colao, M.D., Ph.D., Antonella Di Sarno, M.D., Ph.D., Paolo Cappabianca, M.D., Carolina
More informationHigh and Low GH: an update of diagnosis and management of GH disorders
High and Low GH: an update of diagnosis and management of GH disorders Georgia Chapter-AACE 2017 Laurence Katznelson, MD Professor of Medicine and Neurosurgery Associate Dean of Graduate Medical Education
More informationQuinagolide a valuable treatment option for hyperprolactinaemia
European Journal of Endocrinology (2006) 154 187195 ISSN 0804-4643 REVIEW Quinagolide a valuable treatment option for hyperprolactinaemia Anne Barlier and Philippe Jaquet Interactions Cellulaires Neuroendocriniennes,
More informationEndocrine part two. Presented by Dr. Mohammad Saadeh The requirements for the Clinical Chemistry Philadelphia University Faculty of pharmacy
Endocrine part two Presented by Dr. Mohammad Saadeh The requirements for the Clinical Chemistry Philadelphia University Faculty of pharmacy Cushing's disease: increased secretion of adrenocorticotropic
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Acquired hypogonadism, prevalence of, 165 167 primary, 165 secondary, 167 Adipose tissue, as an organ, 240 241 Adrenal hyperplasia, congenital,
More informationMultiple vertebral fractures in an elderly male with macroprolactinoma
Case report Multiple vertebral fractures in an elderly male with macroprolactinoma Saša Magaš 1, Miroslav Ćaćić 2, Zrinka Sudar Magaš 3, Ivan Kruljac 2 1 Vuk Vrhovac Clinic for Diabetes, Endocrinology
More informationEndocrinological Outcome Among Treated Craniopharyngioma Patients
Endocrinological Outcome Among Treated Craniopharyngioma Patients Afaf Al Sagheir, MD Head & Consultant, Section of Endocrinology/Diabetes Department of Pediatrics KFSH&RC Introduction Craniopharyngiomas
More informationGUIDELINES ON. Introduction. G.R. Dohle, S. Arver, C. Bettocchi, S. Kliesch, M. Punab, W. de Ronde
GUIDELINES ON Male Hypogonadism G.R. Dohle, S. Arver,. Bettocchi, S. Kliesch, M. Punab, W. de Ronde Introduction Male hypogonadism is a clinical syndrome caused by androgen deficiency. It may adversely
More informationUrgent and Emergent Pituitary Conditions
Urgent and Emergent Pituitary Conditions PANKAJ A. GORE, MD DIRECTOR, BRAIN AND SKULL BASE T UMOR SURGERY PROVIDENCE B R AIN AND S PINE I NSTITUTE Urgent and Emergent Pituitary Conditions Neurosurgical
More informationIntegrity of the Lactotroph Axis and Antithyroid Antibodies in Patients with Hypopituitarism
Integrity of the Lactotroph Axis and Antithyroid Antibodies in Patients with Hypopituitarism Carolina Garcia Soares Leães Caroline K. Kramer Cristina Micheletto Dallago, MD Miriam da Costa Oliveira, PhD
More informationPeri-op Pituitary / Diabetes Insipidus/ Apoplexy Dr. Stan Van Uum, MD, PhD, FRCPC
10 th Annual Canadian Endocrine Update 3 rd Canadian Endocrine Review Course Peri-op Pituitary / Diabetes Insipidus/ Apoplexy Dr. Stan Van Uum, MD, PhD, FRCPC 10 th Annual Canadian Endocrine Update Dr.
More informationHypothalamus & Pituitary Gland
Hypothalamus & Pituitary Gland Hypothalamus and Pituitary Gland The hypothalamus and pituitary gland form a unit that exerts control over the function of several endocrine glands (thyroid, adrenals, and
More informationProlactinoma and pregnancy
British Journal of Obstetrics and Gynaecology September 2000, Vol107, pp. 1064-1068 REVIEW Prolactinoma and pregnancy Introduction Hyperprolactinaemia, a common endocrine disorder, frequently leads to
More informationPituitary gland Pituitary fossa Mass: 5 gms DIMENSIONS 7mm (Ht) 9mm (AP) 11m(transverse) originates from Rathke s pouch and infundibulum
Pituitary gland Pituitary fossa Mass: 5 gms DIMENSIONS 7mm (Ht) 9mm (AP) 11m(transverse) originates from Rathke s pouch and infundibulum Cell type hormone Clinical syndrome Tumor type Somatotroph Growth
More informationPRIMARY AMENORRHEA AND PITUITARY ADENOMAS
FERTIUTY AND STERILITY Copight c 1981 The American Fertility Society Vol. 35, No.6, June 1981 Printed in U.SA. PRIMARY AMENORRHEA AND PITUITARY ADENOMAS CAROLYN B. COULAM, M.D.* EDWARD R. LAWS, JR., M.D.t
More informationCY Tse, AMK Chow, SCS Chan. Introduction
Effects of an extended-interval dosing regimen of triptorelin depot on the hormonal profile of patients with endometriosis: prospective observational study CY Tse, AMK Chow, SCS Chan Objective. To evaluate
More informationM0BCore Safety Profile. Active substance: Triptorelin Pharmaceutical form(s)/strength: 0,1 mg P-RMS: DE/H/PSUR/0038/002 Date of FAR:
M0BCore Safety Profile Active substance: Triptorelin Pharmaceutical form(s)/strength: 0,1 mg P-RMS: DE/H/PSUR/0038/002 Date of FAR: 26.05.2014 4.3 Contraindications Hypersensitivity to GnRH, its analogues
More informationX/00/$03.00/0 Vol. 85, No. 5 The Journal of Clinical Endocrinology & Metabolism Copyright 2000 by The Endocrine Society
0021-972X/00/$03.00/0 Vol. 85, No. 5 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 2000 by The Endocrine Society The Dominant Role of Increased Intrasellar Pressure in
More informationClinical presentations of endocrine diseases
Section I Chapter 1 Clinical approaches Clinical presentations of endocrine diseases Karen Gomez-Hernandez and Shereen Ezzat Endocrinology is a fascinating field that covers a wide range of diseases with
More informationHormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline Task Force Members Maria Fleseriu, MD Ibrahim A. Hashim, PhD Niki Karavitaki, PhD Shlomo Melmed, MD M.
More informationORIGINAL ARTICLE Importance of screening for macroprolactin in all hyperprolactinaemic sera
Malaysian J Pathol 2013; 35(1) : 59 63 ORIGINAL ARTICLE Importance of screening for macroprolactin in all hyperprolactinaemic sera Farhi Ain JAMALUDDIN, Pavai STHANESHWAR, Zanariah HUSSEIN, Nor ashikin
More informationImaging pituitary gland tumors
November 2005 Imaging pituitary gland tumors Neel Varshney,, Harvard Medical School Year IV Two categories of presenting signs of a pituitary mass Functional tumors present with symptoms due to excess
More informationDRUG NAME: Cabergoline
DRUG NAME: Cabergoline SYNONYM(S): COMMON TRADE NAME(S): DOSTINEX CLASSIFICATION: hormonal agent Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM
More informationAcromegaly: Management of the Patient Who Has Failed Surgery
Acromegaly: Management of the Patient Who Has Failed Surgery Minnesota/Midwest Chapter of the American Association of Clinical Endocrinologists 8 th Annual Meeting October 14, 2017 Mark E. Molitch, M.D.
More informationManaging Acromegaly: Review of Two Cases
Managing Acromegaly: Review of Two Cases INDICATION AND USAGE SIGNIFOR LAR (pasireotide) for injectable suspension is a somatostatin analog indicated for the treatment of patients with acromegaly who have
More informationProlactinomas. clinical practice. The Clinical Problem. Anne Klibanski, M.D.
The new england journal of medicine clinical practice Prolactinomas Anne Klibanski, M.D. This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various
More informationManaging Acromegaly: Biochemical Control with SIGNIFOR LAR (pasireotide)
Managing Acromegaly: Biochemical Control with SIGNIFOR LAR (pasireotide) INDICATION AND USAGE SIGNIFOR LAR (pasireotide) for injectable suspension is a somatostatin analog indicated for the treatment of
More informationTHE ANTERIOR PITUITARY. Embryology cont. Embryology of the pituitary BY MISPA ZUH HS09A179. Embryology cont. THE PITUIYARY GLAND Anatomy:
THE ANTERIOR PITUITARY BY MISPA ZUH HS09A179 Embryology of the pituitary The pituitary is formed early in embryonic life from the fusion of the Rathke s pouch (anterior) and the diencephalon ( posterior)
More informationwww.iffs-reproduction.org @IntFertilitySoc Int@FedFertilitySoc Conflict of interest none Outline Causes of ovulatory dysfunction Assessment of women with ovulatory dysfunction Management First line Second
More informationJMSCR Vol 05 Issue 01 Page January 2017
MEN1, AIP, PRKAR1A and CDKN1B are familial pituitary syndromes found to be associated with four different genes. Pituitary gland is situated in hypophyseal fossa which is bounded supero-laterally by dural
More informationDIMENSIONS 1 cm in diameter 0.5 to 1 gm in weight. LOCATION Sella turcica A bony cavity. DIVISIONS Anterior lobe Posterior lobe Pars intermedia
DIMENSIONS 1 cm in diameter 0.5 to 1 gm in weight LOCATION Sella turcica A bony cavity DIVISIONS Anterior lobe Posterior lobe Pars intermedia body temperature autonomic nervous system emotional and food
More informationSomatotroph Pituitary Adenomas (Acromegaly) The Diagnostic Pathway (11-2K-234)
Somatotroph Pituitary Adenomas (Acromegaly) The Diagnostic Pathway (11-2K-234) Common presenting symptoms/clinical assessment: Pituitary adenomas are benign neoplasms of the pituitary gland. In patients
More informationin Primary Care (Part 2) Jonathan R. Anolik, MD, FACP, FACE Lewis Katz School of Medicine at Temple University
Common Endocrine Problems Seen in Primary Care (Part 2) Lecture #34 Jonathan R. Anolik, MD, FACP, FACE Lewis Katz School of Medicine at Temple University None Conflict of Interest Topics to be Covered
More informationAndrogen deficiency. Dr Rakesh Iyer Staff Specialist in Endocrinology Calvary hospital
Androgen deficiency Dr Rakesh Iyer Staff Specialist in Endocrinology Calvary hospital Outline Pathological androgen deficiency - Background, causes, interpretation - Indications for treatment Androgen
More informationEndocrine system overview
Endocrine system overview Nature of the hormonal system -Major integrator of body function Classification of hormones Endocrine vs paracrine Nature of hormone-receptor systems Role of the hypothalamuspituitary
More information1. Comprehensive assessment undertaken prior to initiating an opioid (Pain assessment as per UCLH history taking Performa)
OPIOID TRACKER CARD Name DOB Sex Hospital Number Diagnosis FOR NEW PRESCRIPTIONS OPIOID PRESCRIPTION CHECKLIST 1. Comprehensive assessment undertaken prior to initiating an opioid (Pain assessment as per
More informationAntipituitary Antibodies in Idiopathic Hyperprolactinemic Patients
Antipituitary Antibodies in Idiopathic Hyperprolactinemic Patients ANNAMARIA DE BELLIS, a ANNAMARIA COLAO, c ROSARIO PIVONELLO, c ANTONELLA SAVOIA, a MARINA BATTAGLIA, a GIUSEPPE RUOCCO, a GILDA TIRELLI,
More informationAutoimmune hypophysitis may eventually become empty sella
Neuroendocrinology Letters Volume 34 No. 2 2013 Autoimmune hypophysitis may eventually become empty sella Hua Gao*, You-you Gu*, Ming-cai Qiu Department of Endocrinology, Tianjin Medical University General
More informationGONADAL FUNCTION: An Overview
GONADAL FUNCTION: An Overview University of PNG School of Medicine & Health Sciences Division of Basic Medical Sciences Clinical Biochemistry BMLS III & BDS IV VJ Temple 1 What are the Steroid hormones?
More information(3) Pituitary tumours
Hypopituitarism Diabetes Insipidus Pituitary tumours (2) Dr T Kemp - Endocrinology and Metabolism Unit - Steve Biko Academic Hospital (3) Pituitary tumours Pituitary microadenoma - intrasellar adenoma
More informationHyperprolactinemia. Justin Moore, MD
Hyperprolactinemia Justin Moore, MD Biography.com The Miraculous Lactation of St. Bernard Bernard prayed before a statue of the Madonna, asking her, "Show yourself a mother" ("Monstra te esse Matrem").
More information